These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 27178147)

  • 1. Case of hypophysitis caused by nivolumab.
    Ishikawa M; Oashi K
    J Dermatol; 2017 Jan; 44(1):109-110. PubMed ID: 27178147
    [No Abstract]   [Full Text] [Related]  

  • 2. Immune Checkpoint Inhibitor-Associated Central Adrenal Insufficiency.
    Mishra T; He G; Sreeram K; Rauf M; Subahi A; Hazem M
    Am J Ther; 2019; 26(5):e626-e627. PubMed ID: 30277909
    [No Abstract]   [Full Text] [Related]  

  • 3. Secondary Adrenal Insufficiency Following Nivolumab Therapy in a Patient with Metastatic Renal Cell Carcinoma.
    Seki T; Yasuda A; Oki M; Kitajima N; Takagi A; Nakajima N; Miyajima A; Fukagawa M
    Tokai J Exp Clin Med; 2017 Sep; 42(3):115-120. PubMed ID: 28871578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolated Adrenocorticotropic Hormone Deficiency Caused by Nivolumab in a Patient with Metastatic Lung Cancer.
    Takaya K; Sonoda M; Fuchigami A; Hiyoshi T
    Intern Med; 2017 Sep; 56(18):2463-2469. PubMed ID: 28824067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma.
    Okano Y; Satoh T; Horiguchi K; Toyoda M; Osaki A; Matsumoto S; Tomaru T; Nakajima Y; Ishii S; Ozawa A; Shibusawa N; Shimada T; Higuchi T; Chikamatsu K; Yamada M
    Endocr J; 2016 Oct; 63(10):905-912. PubMed ID: 27440480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nivolumab-induced hypophysitis causing secondary adrenal insufficiency after transient ACTH elevation.
    Sekizaki T; Kameda H; Oba C; Yong Cho K; Nakamura A; Miyoshi H; Osawa T; Shinohara N; Atsumi T
    Endocr J; 2019 Oct; 66(10):937-941. PubMed ID: 31217401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab.
    Brilli L; Danielli R; Ciuoli C; Calabrò L; Di Giacomo AM; Cerase A; Paffetti P; Sestini F; Porcelli B; Maio M; Pacini F
    Endocrine; 2017 Dec; 58(3):535-541. PubMed ID: 28401443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolated Adrenocorticotropin Deficiency due to Nivolumab-induced Hypophysitis in a Patient with Advanced Lung Adenocarcinoma: A Case Report and Literature Review.
    Ohara N; Ohashi K; Fujisaki T; Oda C; Ikeda Y; Yoneoka Y; Hashimoto T; Hasegawa G; Suzuki K; Takada T
    Intern Med; 2018 Feb; 57(4):527-535. PubMed ID: 29151505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nivolumab-induced Hypophysitis, Secondary Adrenal Insufficiency and Destructive Thyroiditis in a Patient with Lung Adenocarcinoma.
    Mishima Y; Fukaishi T; Inase N; Isogai S
    Intern Med; 2019 Mar; 58(5):693-697. PubMed ID: 30449786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corticotropic insufficiency in a monocentric prospective cohort of patients with lung cancer treated with nivolumab: Prevalence and etiology.
    Ducloux R; Tavernier JY; Wojewoda P; Toullet F; Romanet S; Averous V
    Ann Endocrinol (Paris); 2021 Feb; 82(1):8-14. PubMed ID: 33290748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nivolumab-induced hypothyroidism followed by isolated ACTH deficiency.
    Martins Machado C; Almeida Santos L; Barroso A; Oliveira MJ
    BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31466960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypophysitis: Nursing Management of Immune-Related Adverse Events
.
    Vazquez A
    Clin J Oncol Nurs; 2017 Apr; 21(2):154-156. PubMed ID: 28315541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late-onset hypophysitis after discontinuation of nivolumab treatment for advanced skin melanoma: a case report.
    Antoniou S; Bazazo G; Röckl L; Papadakis M; Berg C
    BMC Endocr Disord; 2021 Sep; 21(1):191. PubMed ID: 34544399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint inhibitor-induced hypophysitis with transient ACTH-dependent hypercortisolism.
    AlRubaish FA; Gupta N; Shi MZ; Christopoulos S
    BMJ Case Rep; 2024 May; 17(5):. PubMed ID: 38772867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nivolumab in previously untreated melanoma without BRAF mutation.
    Robert C; Long GV; Brady B; Dutriaux C; Maio M; Mortier L; Hassel JC; Rutkowski P; McNeil C; Kalinka-Warzocha E; Savage KJ; Hernberg MM; Lebbé C; Charles J; Mihalcioiu C; Chiarion-Sileni V; Mauch C; Cognetti F; Arance A; Schmidt H; Schadendorf D; Gogas H; Lundgren-Eriksson L; Horak C; Sharkey B; Waxman IM; Atkinson V; Ascierto PA
    N Engl J Med; 2015 Jan; 372(4):320-30. PubMed ID: 25399552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Swinging for the Fences: Long-Term Survival With Ipilimumab in Metastatic Melanoma.
    Gibney GT; Atkins MB
    J Clin Oncol; 2015 Jun; 33(17):1873-7. PubMed ID: 25964248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel melanoma therapies and their side effects.
    González N; Ratner D
    Cutis; 2016 Jun; 97(6):426-8. PubMed ID: 27416087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nivolumab-induced hypophysitis leading to hypopituitarism and secondary empty sella syndrome in a patient with non-small cell lung cancer.
    Chang J; Tran J; Kamel D; Basu A
    BMJ Case Rep; 2019 Mar; 12(3):. PubMed ID: 30850565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nivolumab induced hypophysitis in a patient with recurrent non-small cell lung cancer.
    Kajal S; Gupta P; Ahmed A; Gupta A
    Drug Discov Ther; 2021 Sep; 15(4):218-221. PubMed ID: 34456195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cortisol in the Evaluation of Adrenal Insufficiency.
    Hannah-Shmouni F; Demidowich A; Stratakis CA
    JAMA; 2016 Aug; 316(5):535-6. PubMed ID: 27483068
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.